BNP Paribas Financial Markets
CTKB icon

BNP Paribas Financial Markets’s Cytek Biosciences CTKB Stock Holding History

BNP Paribas Financial Markets’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$341K Sell
78,044
-28,238
-27% -$133K ﹤0.01% 3788
2025
Q4 		$537K Buy
106,282
+82,466
+346% +$383K ﹤0.01% 3534
2025
Q3 		$82.6K Buy
23,816
+11,838
+99% +$44.4K ﹤0.01% 4382
2025
Q2 		$40.7K Sell
11,978
-81,853
-87% -$273K ﹤0.01% 4336
2025
Q1 		$376K Sell
93,831
-114,833
-55% -$595K ﹤0.01% 3336
2024
Q4 		$1.35M Buy
+208,664
New +$1.24M ﹤0.01% 2626

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets's CTKB Position: Q1 2026 in Review

BNP Paribas Financial Markets reduced its Cytek Biosciences (CTKB) stake by 27% in Q1 2026, selling an estimated $133K and leaving 78,044 shares worth $341K. The position accounts for ﹤0.01% of the portfolio, ranked #3788.

BNP Paribas Financial Markets first reported a position in CTKB in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.35M in Q4 2024. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • BNP Paribas Financial Markets held 78,044 shares of Cytek Biosciences worth $341K as of Q1 2026.
  • BNP Paribas Financial Markets sold 28,238 Cytek Biosciences shares in Q1 2026, an estimated $133K.
  • Cytek Biosciences made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #3788 holding.
  • BNP Paribas Financial Markets first reported a position in Cytek Biosciences in Q4 2024 and has held it in 6 quarters since.
  • BNP Paribas Financial Markets's Cytek Biosciences position peaked at $1.35M in Q4 2024.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.